Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1080/15321819.2020.1865400 http://scihub22266oqcxt.onion/10.1080/15321819.2020.1865400 33393415!ä!33393415 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Immunoassay+Immunochem 2020 ; 41 (6): 960-975 Nephropedia Template TP {{tp|p=33393415|t=2020. Immunotherapies and COVID-19 related Neurological manifestations: A Comprehensive Review Article |pdf=|usr=}}{{33393415}} gab.com Text Immunotherapies and COVID-19 related Neurological manifestations: A Comprehensive Review Article JO: J Immunoassay Immunochem http://www.kidney.de/pget.php?&tw=1&pmid=33393415 #FOAvip In December 2019, an outbreak of pandemic severe respiratory distress syndrome coronavirus disease 2019 (COVID-19) initially occurred in China, has spread the world resulted in serious threats to human public health. Uncommon neurological manifestations with pathophysiological symptoms were observed in infected patients including headache, seizures, and neuroimmunological disorders. Regardless of whether these neurological symptoms are direct or indirect casual infection relationship, this novel viral infection has a relevant impact on the neuroimmune system that requires a neurologist's careful assessment. Recently, the use of immunotherapy has been emerged in fighting against COVID-19 infection despite the uncertain efficiency in managing COVID-19 related disorders or even its proven failure by increasing its severity. Herein, the author is addressing the first approaches in using immunotherapies in controlling COVID-19 viral impact on the brain by highlighting their role in decreasing or increasing infection risks among subjects. This point of view review article supports the use of immunotherapies in managing COVID-19 neurological disorders but in optimal timing and duration to ensure the maximum therapeutic outcome by reducing morbidity and mortality rate. Based on recently published data, the current review article highlights the beneficial effects and drawbacks of using immunotherapies to combat COVID-19 and its neurological symptoms. Twit Text FOAVip Immunotherapies and COVID-19 related Neurological manifestations: A Comprehensive Review Article ????J Immunoassay Immunochem http://www.kidney.de/pget.php?&tw=1&pmid=33393415 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33393415 #FOAvip English Wikipedia <ref>{{Cite pmid|33393415}}</ref> Immunotherapies and COVID-19 related Neurological manifestations: A Comprehensive Review Article #MMPMID33393415 Anwar MM J Immunoassay Immunochem 2020[Nov]; 41 (6): 960-975 PMID33393415show ga In December 2019, an outbreak of pandemic severe respiratory distress syndrome coronavirus disease 2019 (COVID-19) initially occurred in China, has spread the world resulted in serious threats to human public health. Uncommon neurological manifestations with pathophysiological symptoms were observed in infected patients including headache, seizures, and neuroimmunological disorders. Regardless of whether these neurological symptoms are direct or indirect casual infection relationship, this novel viral infection has a relevant impact on the neuroimmune system that requires a neurologist's careful assessment. Recently, the use of immunotherapy has been emerged in fighting against COVID-19 infection despite the uncertain efficiency in managing COVID-19 related disorders or even its proven failure by increasing its severity. Herein, the author is addressing the first approaches in using immunotherapies in controlling COVID-19 viral impact on the brain by highlighting their role in decreasing or increasing infection risks among subjects. This point of view review article supports the use of immunotherapies in managing COVID-19 neurological disorders but in optimal timing and duration to ensure the maximum therapeutic outcome by reducing morbidity and mortality rate. Based on recently published data, the current review article highlights the beneficial effects and drawbacks of using immunotherapies to combat COVID-19 and its neurological symptoms. |Brain/pathology[MESH] |COVID-19/complications/*immunology/*therapy[MESH] |Cladribine/therapeutic use[MESH] |Cytokine Release Syndrome/therapy/*virology[MESH] |Cytokines/immunology[MESH] |Glucocorticoids/therapeutic use[MESH] |Headache/virology[MESH] |Humans[MESH] |Immunoglobulins, Intravenous/therapeutic use[MESH] |Immunotherapy/*methods[MESH] |Interferon-beta/immunology[MESH] |Interleukin-6/immunology[MESH] |Nervous System Diseases/*immunology/*therapy/virology[MESH]Immunotherapies and COVID-19 related Neurological manifestations: A Co(epmc).pdf DeepDyve Pubget Overpricing